1
|
Smith RE, Reyes NJ, Khandelwal P, Schlereth SL, Lee HS, Masli S, Saban DR. Secondary allergic T cell responses are regulated by dendritic cell-derived thrombospondin-1 in the setting of allergic eye disease. J Leukoc Biol 2016; 100:371-80. [PMID: 26856994 PMCID: PMC4945354 DOI: 10.1189/jlb.3a0815-357rr] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2015] [Revised: 01/19/2016] [Accepted: 01/21/2016] [Indexed: 11/24/2022] Open
Abstract
Allergic eye disease, as in most forms of atopy, ranges in severity among individuals from immediate hypersensitivity to a severe and debilitating chronic disease. Dendritic cells play a key role in stimulating pathogenic T cells in allergen re-exposure, or secondary responses. However, molecular cues by dendritic cells underpinning allergic T cell response levels and the impact that this control has on consequent severity of allergic disease are poorly understood. Here, we show that a deficiency in thrombospondin-1, a matricellular protein known to affect immune function, has subsequent effects on downstream T cell responses during allergy, as revealed in an established mouse model of allergic eye disease. More specifically, we demonstrate that a thrombospondin-1 deficiency specific to dendritic cells leads to heightened secondary T cell responses and consequent clinical disease. Interestingly, whereas thrombospondin-1-deficient dendritic cells augmented activity of allergen-primed T cells, this increase was not recapitulated with naïve T cells in vitro. The role of dendritic cell-derived thrombospondin-1 in regulating secondary allergic T cell responses was confirmed in vivo, as local transfer of thrombospondin-1-sufficient dendritic cells to the ocular mucosa of thrombospondin-1 null hosts prevented the development of augmented secondary T cell responses and heightened allergic eye disease clinical responses. Finally, we demonstrate that topical instillation of thrombospondin-1-derived peptide reduces T cell activity and clinical progression of allergic eye disease. Taken together, this study reveals an important modulatory role of dendritic cell-derived thrombospondin-1 on secondary allergic T cell responses and suggests the possible dysregulation of dendritic cell-derived thrombospondin-1 expression as a factor in allergic eye disease severity.
Collapse
Affiliation(s)
- R E Smith
- Department of Ophthalmology, Duke University School of Medicine, Durham, North Carolina, USA
| | - N J Reyes
- Department of Ophthalmology, Duke University School of Medicine, Durham, North Carolina, USA
| | - P Khandelwal
- Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
| | - S L Schlereth
- Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
| | - H S Lee
- Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
| | - S Masli
- Department of Ophthalmology, Boston University Medical Center, Boston, Massachusetts, USA; and
| | - D R Saban
- Department of Ophthalmology, Duke University School of Medicine, Durham, North Carolina, USA; Department of Immunology, Duke University School of Medicine, Durham, North Carolina, USA;
| |
Collapse
|
2
|
Hazra S, Jarajapu YPR, Stepps V, Caballero S, Thinschmidt JS, Sautina L, Bengtsson N, LiCalzi S, Dominguez J, Kern TS, Segal MS, Ash JD, Saban DR, Bartelmez SH, Grant MB. Long-term type 1 diabetes influences haematopoietic stem cells by reducing vascular repair potential and increasing inflammatory monocyte generation in a murine model. Diabetologia 2013; 56. [PMID: 23192694 PMCID: PMC3773610 DOI: 10.1007/s00125-012-2781-0] [Citation(s) in RCA: 70] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
AIMS/HYPOTHESIS We sought to determine the impact of long-standing type 1 diabetes on haematopoietic stem/progenitor cell (HSC) number and function and to examine the impact of modulating glycoprotein (GP)130 receptor in these cells. METHODS Wild-type, gp130(-/-) and GFP chimeric mice were treated with streptozotocin to induce type 1 diabetes. Bone marrow (BM)-derived cells were used for colony-formation assay, quantification of side population (SP) cells, examination of gene expression, nitric oxide measurement and migration studies. Endothelial progenitor cells (EPCs), a population of vascular precursors derived from HSCs, were compared in diabetic and control mice. Cytokines were measured in BM supernatant fractions by ELISA and protein array. Flow cytometry was performed on enzymatically dissociated retina from gfp(+) chimeric mice and used to assess BM cell recruitment to the retina, kidney and blood. RESULTS BM cells from the 12-month-diabetic mice showed reduced colony-forming ability, depletion of SP-HSCs with a proportional increase in SP-HSCs residing in hypoxic regions of BM, decreased EPC numbers, and reduced eNos (also known as Nos3) but increased iNos (also known as Nos2) and oxidative stress-related genes. BM supernatant fraction showed increased cytokines, GP130 ligands and monocyte/macrophage stimulating factor. Retina, kidney and peripheral blood showed increased numbers of CD11b(+)/CD45(hi)/ CCR2(+)/Ly6C(hi) inflammatory monocytes. Diabetic gp130(-/-) mice were protected from development of diabetes-induced changes in their HSCs. CONCLUSIONS/INTERPRETATION The BM microenvironment of type 1 diabetic mice can lead to changes in haematopoiesis, with generation of more monocytes and fewer EPCs contributing to development of microvascular complications. Inhibition of GP130 activation may serve as a therapeutic strategy to improve the key aspects of this dysfunction.
Collapse
Affiliation(s)
- S. Hazra
- Pharmacology & Therapeutics, University of Florida, 1600 SW Archer Road, Academic Research Building, PO 100267, Gainesville, FL 32610-0267, USA
| | - Y. P. R. Jarajapu
- Pharmacology & Therapeutics, University of Florida, 1600 SW Archer Road, Academic Research Building, PO 100267, Gainesville, FL 32610-0267, USA
| | - V. Stepps
- BetaStem Therapeutics Inc, San Francisco, CA, USA
| | - S. Caballero
- Pharmacology & Therapeutics, University of Florida, 1600 SW Archer Road, Academic Research Building, PO 100267, Gainesville, FL 32610-0267, USA
| | - J. S. Thinschmidt
- Pharmacology & Therapeutics, University of Florida, 1600 SW Archer Road, Academic Research Building, PO 100267, Gainesville, FL 32610-0267, USA
| | - L. Sautina
- Division of Nephrology/Department of Medicine, University of Florida, Gainesville, FL, USA
| | - N. Bengtsson
- Pharmacology & Therapeutics, University of Florida, 1600 SW Archer Road, Academic Research Building, PO 100267, Gainesville, FL 32610-0267, USA
| | - S. LiCalzi
- Pharmacology & Therapeutics, University of Florida, 1600 SW Archer Road, Academic Research Building, PO 100267, Gainesville, FL 32610-0267, USA
| | - J. Dominguez
- Pharmacology & Therapeutics, University of Florida, 1600 SW Archer Road, Academic Research Building, PO 100267, Gainesville, FL 32610-0267, USA
| | - T. S. Kern
- Case Western Reserve University and Louis Stokes Veterans Administration Hospital, Cleveland, OH, USA
| | - M. S. Segal
- Division of Nephrology/Department of Medicine, University of Florida, Gainesville, FL, USA
| | - J. D. Ash
- University of Oklahoma, Oklahoma City, OK, USA
| | - D. R. Saban
- Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA
| | | | - M. B. Grant
- Pharmacology & Therapeutics, University of Florida, 1600 SW Archer Road, Academic Research Building, PO 100267, Gainesville, FL 32610-0267, USA
| |
Collapse
|